Abstract
This study was designed to investigate the effect of 1 month treatment with nateglinide, rosiglitazone, metformin and their different combinations on streptozotocin (STZ) diabetic rats. Methods Diabetes was induced by a single intraperitoneal injection of STZ at a dose 55 mg kg −1. The plasma glucose, total lipid, cholesterol, triglyceride and protein components were measured before and 15 and 30 days after the administration of the antidiabetic agents. Results After the treatment, a significant reduction was observed in fasting blood glucose levels in all groups. Rosiglitazone or metformin were found to exhibit a hypolipidaemic effect in diabetic rats when administered alone or in combination. In comparison, nateglinide, when used alone, resulted in a significant increase in cholesterol and total lipid levels. This effect was masked when nateglinide was administered concurrently with metformin and hypolipidaemic effect was noticed. Conclusions Results from this study suggest that compared with nateglinide, rosiglitazone has a more favorable effect on the lipid profile in STZ-induced diabetes in rats.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
